Siedler G, Macha K, Stoll S, Plechschmidt J, Wang R, Gerner S, Strasser E, Schwab S, Kallmünzer B (2022)
Publication Type: Journal article
Publication year: 2022
DOI: 10.1111/jth.15677
Background: Patients with atrial fibrillation have a relevant risk for ischemic stroke despite the recommended use of direct oral anticoagulants (DOAC). The risk correlates with the functional DOAC plasma levels in clinical trials, but the value of their measurement in community use remains undetermined. Objectives: We aim to investigate the clinical implications and the prognostic value of DOAC plasma level measurement during steady state. Methods: In this observational clinical cohort study among patients with ischemic stroke and atrial fibrillation, 397 individuals on oral anticoagulants for secondary stroke prevention were included between 2016 and 2020. The functional DOAC plasma levels were measured during steady state. Early stroke recurrence within 3 months was recorded as the main outcome parameter. Results: Three hundred ninety-seven patients (201 female, mean age 78 [±9] years, median CHA
APA:
Siedler, G., Macha, K., Stoll, S., Plechschmidt, J., Wang, R., Gerner, S.,... Kallmünzer, B. (2022). Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention. Journal of Thrombosis and Haemostasis. https://doi.org/10.1111/jth.15677
MLA:
Siedler, Gabriela, et al. "Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention." Journal of Thrombosis and Haemostasis (2022).
BibTeX: Download